05:24 AM EDT, 09/16/2026 (MT Newswires) -- Mendus (IMMU.ST) said Wednesday that it began the phase 1b study for its acute myeloid leukemia, or AML, combo treatment. The Diva study will review the safety and immune activity of AML patients with measurable residual disease dosed with vididencel in combination with venetoclax and azacitidine. Additionally, the study aims to see if there is a decrease in measurable residual disease among patients. The biopharmaceutical company expects a safety readout to be published in the first half of 2027, with initial topline data release in the second half of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.